Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: Results from the RISCAVID study

Journal of Nephrology

Volumn 23, Issue 5, 2010, Pages 556-562

  Panichi, Vincenzo ^a   Bigazzi, Roberto ^b   Paoletti, Sabrina ^a   Mantuano, Emanuela ^b   Beati, Sara ^a   Marchetti, Valentina ^c   Bernabini, Giada ^a   Grazi, Giovanni ^c   Giusti, Riccardo ^d   Rosati, Alberto ^d   Migliori, Massimiliano ^a   Betti, Giancarlo ^d   Pasquariello, Antonio ^e   Panicucci, Erica ^f   Barsotti, Giuliano ^f   Bellasi, Antonio ^g  

^a Versilia Hospital   (Italy)

^b Livorno Hospital   (Italy)

^c Pontedera Hospital   (Italy)

^d Lucca Hospital   (Italy)

^e University Hospital in Pisa   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

All cause mortality; Cardiovascular mortality; Hemodialysis; Phosphate; Sevelamer

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

AGED; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EUROPE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; PROSPECTIVE STUDY; UNITED STATES;

AGED; CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 78049383138     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. USRDS. The United States Renal Data System. http://www.usrds.org/adr.htm, 2007.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218. (Pubitemid 39031360)
3. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770-779.
4. Tentori F, Blayney M, Albert J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519-530.
5. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-1187.
6. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.
7. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
8. Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009;22:59-68
9. Esposito MG, Cesare CM, De Santo RM, et al. Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol. 2008;21(Suppl 13):S92-S96.
10. Cannata-Andia JB, Fernández-Martín JL, Zoccali C, et al. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol. 2008;21:290-298
11. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1423-1429.
12. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470-473. (Pubitemid 15227507)
13. Foley RN, Wang C, Ishani A, Collins AJ. NHANES III: influence of race on GFR thresholds and detection of metabolic abnormalities. J Am Soc Nephrol. 2007;18:2575-2582 (Pubitemid 47378874)
14. Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int. 2008;73:956-962.
15. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592
16. Onufrak SJ, Bellasi A, Cardarelli F, et al. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol. 2009;169:67-77.
17. Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol. 2002;13:1046-1054.
18. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 2007;20:295-301.
19. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial. 2003;16:186-188.
20. Covic A, Kothawala P, Bemal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1506-1523.
21. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-441.
22. Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther. 2007;32:617-624. (Pubitemid 350135118)
23. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130-1137.
24. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815-1824.
25. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
26. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255-1261
27. Goodman WG, Goldin J, Kuizon BD, et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
28. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695-701